New drug cocktails show promise for multiple myeloma patients

NCT ID NCT02203643

Completed Disease control Sponsor: Mario Boccadoro Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested different combinations of cancer drugs (carfilzomib, cyclophosphamide, lenalidomide, and dexamethasone) in 477 adults newly diagnosed with multiple myeloma who were eligible for a stem cell transplant. The goal was to see which combination worked best before and after transplant, or as a longer treatment without transplant. The study also compared two maintenance therapies to keep the disease under control.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Carfilzomib, cyclophosphamide, lenalidomide, and dexamethasone
What this could lead to: If successful, this could point toward more effective treatment combinations for multiple myeloma, potentially improving response rates and delaying disease progression.
What could go wrong: This is a phase 2 trial, so results are preliminary. The drug combinations may cause significant side effects, and not all patients may benefit equally.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA (MM) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

plasma cell myeloma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MULTIPLE MYELOMA (MM)

Contacts and locations

Locations

IRCCS--CROB --CROB di Rionero in di Rionero in Vulture

Rionero in Vulture, 85028, Italy

More trials for these conditions

Other studies related to the condition(s) this trial covers.